Table 1.

Inhibition of HCC827-luc tumor in vivo xenograft recurrence rates by BH3-mimetic ABT-737 treatment in conjunction with EGFR-Inhibitor (Fig. 6E).

Treatment Groups		Xenograft Recurrence Rates (%)
		Day 18		Day 32
III	A	50% (2/4)	50% * (4/8)	75%(3/4)	62.5% † (5/8)
	B	50% (2/4)		50% (2/4)
IV	A	0% (0/6)	0% (0/12)	0% (0/6)	0% (0/12)
	B	0% (0/6)		0% (0/6)

^*p=0.014

^†p=0.004